Biotech Values

[mcbio]

I suppose the potential good news is it implies there is at least strong survival trend from ph2 data for this subgroup [high-expressors of GPNMB in triple-negative breast cancer].

That's a big part of why I'm willing to gamble and hold my position through the results tomorrow. I don't think Mariucci makes those comments just 5 days before the presentation at SABCS if there's not at least an encouraging trend in the data. It would be a moot point if he doesn't have the data at that time; but how likely is that just 5 days in front of the conference and presentation?

FWIW, someone on the YMB posted to note the changes made to the clinicaltrials.gov entry for the 011 trial and how it was edited on 12/3 to eliminate the language that patients would be monitored "for survival information" (
http://finance.yahoo.com/mbview/threadview/?&bn=ef145a6a-8faa-3c06-9031-7248813df2f0&tid=1354821299910-9487150b-259d-4087-8129-de34926d0b11&tls=la%2Cd%2C9 ). They also note that OS was removed as secondary measure on 11/27/12. They then try to spin that as a positive sign, although I don't really follow the logic. I'm not sure this means much of anything but curious to hear any others' thoughts on this. I'm still willing to gamble given the aforementioned comments from the CEO so shortly before the conference.